Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  ipilimumab
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 81 for your search:
Start Over
A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: Ipi4, NCT02068196
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MDX010-20, CA184-002, NCT00094653
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA184-024, NCT00324155
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA184-029, EORTC 18071, NCT00636168
Study of Immunotherapy to Treat Advanced Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA184-043, 2008-003314-97, NCT00861614
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA184-095, 2009-016217-23, NCT01057810
Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA184-104, 2009-017396-19, NCT01285609
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
Phase: Phase III
Type: Supportive care
Status: Closed
Age: 18 to 60
Sponsor: Other
Protocol IDs: IV-ATG-SCT-01, NCT01295710
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA184-156, 2011-000850-48, NCT01450761
Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA184-169, 2011-004029-28, NCT01515189
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA209-067, 2012-005371-13, NCT01844505
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3475-006, 2012-004907-10, NCT01866319
Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: CDR0000287211, NCI-03-C-0109, NCT00058279
Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA184-017 ST, CA184-017, NCT00323882
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2225.00, NCI-2010-00108, K12CA076930, FHCRC-2225.00, IR-6881, BMS-CA184-062, NCT00871481
Doxycycline, Temozolomide and Ipilimumab in Melanoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2011-1165, NCI-2014-01836, NCT01590082
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: INCB 24360-201, NCT01604889
Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: BBI Total Therapy, NCT01743157
Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: VAR0090, NCI-2012-02988, NCT01769222
Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: CDR0000069251, NCI-02-C-0106H, NCI-5743, 5743, NCT00032045
Phase II Randomized Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-010) With or Without gp100 Peptides Emulsified in Montanide ISA-51 in Patients With Stage IV Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-04-C-0083, MDX-010-19, NCI-6532, 6532, NCT00077532
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MDX010-07, CA184-019, NCT00050596
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CDR0000365467, P30CA076292, P30CA014089, MCC-15241, MDX010-16, NCI-6446, CA184-016, 6446, LAC-USC-10M036, NCT00084656
Study of MDX-010 in Stage IV Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MDX010-12, CA184-015, NCT00083278
Start Over